Compare IONQ Inc (IONQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs GeneDx Holdings Corp — how do they compare? IONQ Inc trades at $39.69 (market cap $15.98B), while GeneDx Holdings Corp trades at $68.16 (market cap $2.02B). The key difference: IONQ Inc is far larger — about 7.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 22,848,240). Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and GeneDx Holdings Corp for 19 Days on average.
| IONQ | WGS | |
|---|---|---|
Market Cap | $15.98B | $2.02B |
Volume | 22,848,240 | 734,640 |
Sector | Technology | Health |
52-Week High | $82.09 | $167.51 |
52-Week Low | $26.59 | $34.51 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $13.92B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.63, down 4.14% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported revenue of $130.02M in 2025 but posted a net loss of $510.38M, reflecting negative profit margins of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss after two consecutive beats. Analyst sentiment remains divided with a 50/50 buy/hold split but a consensus price target of $62.75 suggesting significant upside potential from current levels.
The outlook for IONQ hinges on scaling quantum computing technology to justify its premium valuation (P/S 54.74). While strong revenue growth projections and strategic partnerships offer long-term potential, investors face substantial risks from persistent losses, cash burn, and intense competition in the emerging quantum computing sector.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
